Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07516093 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint added 1 → 2 primary endpoints
See other at-risk trials from Nurix Therapeutics, Inc.

Record History

  1. Primary endpoint(s) modified Recruitment opened · Trial sites expanded: 0 → 6 locations · Completion pushed from Jun 2032 to Aug 2033 · 3 morev3 Show 6 more changesShow less
    • Recruitment opened
    • Trial sites expanded: 0 → 6 locations
    • Completion pushed from Jun 2032 to Aug 2033
    • Start date changed from estimate of Jun 2026 to Aug 3, 2026
    • Eligibility criteria revised
    • Secondary endpoints: details revised at 10 of 11 entries

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.
Trial Details
NCT Number NCT07516093
Lead Sponsor Nurix Therapeutics, Inc.
Conditions B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 620 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov